Measuring a lung protein in pulmonary artery hypertension
Part of Lungs & breathing clinical trials.
This study measures how much of a specific lung protein (TSPO) is present in people with pulmonary artery hypertension. The results may help researchers better understand the disease and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent in writing before any study procedures start
- You can comfortably lie flat on your back for up to 90 minutes at a time
- If you could get pregnant, you must have a negative pregnancy test and use very effective birth control
- If you are male and could have a pregnancy partner, you must follow the study’s contraception rules
- You can speak and understand English well enough to follow the study instructions
- You do not have certain blood, kidney, or liver conditions listed by the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
This trial uses a special MRI scan (using xenon gas) to see how well the lungs are working in people with pulmonary arterial hypertension (PAH). It aims to improve diagnosis and monitoring of PAH from connective tissue disease or unknown cause.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
This trial tests a drug that targets a brain protein called TSPO in people with mild to moderate Alzheimer's. It aims to see if this approach can slow memory loss.
This study tests a drug that targets a protein called TSPO to see if it can improve the function of the cells lining the small blood vessels in the brain of people with cerebral small vessel disease. It may help with mild memory or thinking problems.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.